This document discusses optimal strategies for health technology assessment (HTA) and diffusion of new technologies. It outlines a framework involving four stages:
1) Assessment of new technologies through HTA to determine efficacy and effectiveness.
2) Disinvestment of technologies found to be ineffective through HTA evidence.
3) Access to promising technologies with ongoing evidence development.
4) Support for continued innovation through research funding and commercialization partnerships between government, academia and industry.
What’s User Experience and Why Should I Care?Scott Abel
Presented at DocTrain East 2007 by Emily Wiese and Dr. Mike Patterson, APTIMA -- User-friendly. User-centered design. User experience. Experience Design. Human Factors. How many times do you hear these buzz words in your workplace? What does it mean to utilize users input throughout the entire product development lifecycle? How can technical communicators use principles of experience design and human factors to develop products that are both useful and easy-to-use? In this presentation, we will provide a basic introduction to incorporating the users experience into design: what it is, why it’s important, and how it can influence technical communicators work. We will discuss common methods for gathering user requirements, developing user personas, and using this data throughout the product development lifecycle. Case studies will provide insight into what works, what doesn’t, and practical tips for incorporating these methods into your own work.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
What’s User Experience and Why Should I Care?Scott Abel
Presented at DocTrain East 2007 by Emily Wiese and Dr. Mike Patterson, APTIMA -- User-friendly. User-centered design. User experience. Experience Design. Human Factors. How many times do you hear these buzz words in your workplace? What does it mean to utilize users input throughout the entire product development lifecycle? How can technical communicators use principles of experience design and human factors to develop products that are both useful and easy-to-use? In this presentation, we will provide a basic introduction to incorporating the users experience into design: what it is, why it’s important, and how it can influence technical communicators work. We will discuss common methods for gathering user requirements, developing user personas, and using this data throughout the product development lifecycle. Case studies will provide insight into what works, what doesn’t, and practical tips for incorporating these methods into your own work.
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
Medical Imaging - Opportunities for Business Seminar
24/01/12
Short Company Presentations
14 companies took the opportunity to present a short sales pitch of their work and interests to the audience.
Say you want to mobilize service management functionality to field service engineers - how hard can that be?
But:
- what if SAP continuously changes its mind
- what if the engineers already built their own solution
- what if you have outdated SAP systems
- ...
A fairytale of a solution architect that tries to bring relief to field service engineers. What solution is being realized, how did he get so far and now what.
HealthCARE Montana and EdReady June 2015Ryan Schrenk
This presentation was an overview of EdReady with background research, demo/orientation and the start of planning for creation of EdReady goals to help prepare prospective college students for gateway math classes in allied health fields.
Say you want to mobilize service management functionality to field service engineers - how hard can that be?
But:
- what if SAP continuously changes its mind
- what if the engineers already built their own solution
- what if you have outdated SAP systems
- ...
A fairytale of a solution architect that tries to bring relief to field service engineers. What solution is being realized, how did he get so far and now what.
HealthCARE Montana and EdReady June 2015Ryan Schrenk
This presentation was an overview of EdReady with background research, demo/orientation and the start of planning for creation of EdReady goals to help prepare prospective college students for gateway math classes in allied health fields.
Cardium Therapeutics (NYSE MKT: CXM) is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands® nutraceutical business. The Company's lead commercial product, Excellagen® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To Go Brands® develops, markets and sells dietary supplements through established regional and national retailers. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.
News and additional information on Cardium is located at www.cardiumthx.com.
This is a presentation given by Dr. Craig Friderichs at mHealth Summit 2012 on 3 December at a panel session called, "Evidence Matters: mHealth Evidence Status and Approaches."
Rocky Ganske, CEO, Axela Inc., talks about the lessons he's learned as an entrepreneur in the life sciences industry.
Part of the MaRS Future of Medicine(tm) series, an informal moderated forum bringing together research professionals and clinicians interested in drug development.
iNovacia is an established quality provider of lead generation services including high-throughput screening and fragmen based screening. This is supported by a compound collection (ca 300,000 cmpds) and screening libraries of highest international standards with focus on diversity and novelty.
Similar to School Of Public Health Phs 673 March 2010 (20)
University of Victoria ITCH 2009 Feb 22 Plenary Address
School Of Public Health Phs 673 March 2010
1. Avoiding Bedlam: Optimal
Health Technology Diffusion
at the Bedside and Boardroom
Don Juzwishin PhD
Director, Health Technology
Assessment and Innovation
March 17, 2010
2. HTA and Diffusion of Health Technologies
Use
HTA
Disinvestment
Innovation
Obsolescence
HTA
Medical Device
Licensing HTA
Time
Research and Development Experimental Technology Innovative General Use Obsolescence/
Technology Replacement
3. Evidence certain Evidence certain
2. Disinvestment Not effective Effective
1. Assessment
Technology
Ineffective
to be
technology
Certainty of Evidence
adopted
3. Access with
Evidence Development
Promising
technology
4. Innovation
Uncertain evidence Uncertain evidence
Not effective Effective
Effectiveness
4. Alberta Health Services
UNIT Health Technology Assessment, Appraisal and Innovation
FUNCTION
AHS
PROGRAM health
promotion
disease
prevention
public screening diagnosis intervention rehabilitation continuing palliative
health care
OR
SERVICE
5. Federal, provincial and
industry funding
BOSE Biomaterials
and Tissue
Engineering
Integra Nerve Repair
and Regeneration
Biosensors/
BioImaging
Other Technology Health Technology
Development Assessment and Innovation
Centres
Ward of the 21st
Century
Glenrose
Rehabilitation
Hospital
Validation
iRSM
Product Testing &
Alberta Health Services Others Testing &
Development Sites
Industry: SME, MNE
Market Development
Alberta Health and Wellness
Programs
Business Growth
Mentoring
AHS HTAI Ecosystem
International Trade
Technology
Programs
Commercialization
Access to Capital
Facilitation
HQP
• Better
growth
system
products
efficiency
• Increased
• Increased
• Economic
healthcare
valuable IP
demand for
&treatments
• Employment
diversification
• Commercially-
6. Funder of health
IHE
services
U of A
Alberta Health
U of C
and Wellness
ECRI
AHTDP
CADTH
Government
HTA Producers
Funders
Knowledge and
HTA Users Technology
Provider of Creators Research &
health Development
services molecules to
Alberta Health bedside to
Services population
8. Knowledge-to-Action Cycle
Monitor
Knowledge
Use
Select, Tailor,
Implement
Interventions KNOWLEDGE CREATION
Evaluate
Outcomes
Knowledge
Assess Inquiry
Barriers to
Knowledge Use
Synthesis
Sustain
Knowledge
Products/
Use
Tools
Adapt
Knowledge
to Local Context
Identify Problem
Identify, Review,
Select Knowledge Graham et al., 2006